Updates on Overall Survival PARP Inhibitors
In this episode of the IJGC podcast, Editor-in-Ch…
BMJ talk medicine · BMJ Group
July 25, 202235m 20s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Robert Coleman and Shannon Westin to discuss updates on overall survival PARP inhibitors. Robert L. Coleman, MD, is a gynecologic oncologist is Houston Texas and serves as SVP and Chief Scientific Officer for US Oncology Research. His primary research interests are in drug development for gynecological cancers and clinical trial management; he has authored more than 350 peer-reviewed publications. Dr. Shannon Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. She is currently the PI or co-PI for greater than 30 novel treatment trials in gynecologic malignancies.